This site is intended for U.S. Healthcare Professionals only.

In vitro data—INFORM
surveillance study

In vitro activity does not necessarily correlate with clinical efficacy results. Click here for clinical results, including results by pathogen for cUTI trial 1, click here for results for cUTI trial 2, and click here for results for the cIAI trial.

International Network For Optimal Resistance Monitoring (INFORM)1

  • This 2015 US study surveyed the in vitro activity of AVYCAZ and many comparator agents against Gram-negative organisms from 68 medical centers distributed across all 9 US Census regions1
  • A total of 12,250 organisms were collected and tested, including 8793 Enterobacteriaceae and 1809 Pseudomonas aeruginosa strains, among others1
  • For AVYCAZ, FDA susceptibility breakpoints for Enterobacteriaceae (minimum inhibitory concentration [MIC] ≤8/4 mg/L) and P. aeruginosa (MIC ≤8/4 mg/L) were used2
  • For meropenem, 2016 CLSI susceptibility breakpoints for Enterobacteriaceae (MIC ≤1 μg/mL) and P. aeruginosa (MIC ≤2 μg/mL) were used3

CLSI, Clinical and Laboratory Standards Institute.

Bar graph showing AVYCAZ demonstrated >99% susceptibility against Enterobacteriaceae, including isolates producing ESBLs Bar graph showing AVYCAZ demonstrated >99% susceptibility against K. pneumoniae, including isolates producing ESBLs

* E. coli (N=607), K. pneumoniae (N=364), P. mirabilis (N=46), K. oxytoca (N=44).

Meropenem is not shown because all KPC-producing K. pneumoniae isolates tested were nonsusceptible to meropenem.

Bar graph of data on how AVYCAZ demonstrated 98% susceptibility against P. aeruginosa

NS, nonsusceptible.